News

Building 500 prepares to welcome back first science tenant

Posted on 15/02/16

The School of Human and Life Sciences at Canterbury Christ Church University (CCCU) remains on course to open its new industry liaison laboratory at Discovery Park next month.

CCCU will be the first science tenants to move into Building 500, one of the most iconic locations at Discovery Park and the latest building to undergo a major refurbishment.

The industry liaison laboratory will provide the University and its students with first class facilities for science and research, with access to a diverse and dynamic range of pharmaceutical and bio-technology companies.

Genea Biomedx, a world leading company that creates and manufactures practical, accessible and precise fertility technologies that help standardise and automate fertility treatment, and Venomtech, a British company that produces products specifically designed to help solve significant challenges in the discovery of new drug treatments are the first businesses to link up with the university for the new venture.

Canterbury Christ Church University is supporting the partnerships with Genea Biomedx and Venomtech by funding PhD students who will work with them on specific research projects within their area of expertise at the Discovery Park laboratory.

Dr Simon Harvey, Director of Life Sciences at Canterbury Christ Church University, explained:

“This lab will allow us to work directly with industry and support their research and development needs.

“Our staff and students are already working directly with companies at Discovery Park on research that addresses their specific challenges. The industry liaison lab will expand these partnerships, and also allow our undergraduates to experience work in an industry setting and to build the skills needed to work in the sector.

“The University is proud to support research that has contemporary relevance to today’s society and we are delighted to be entering into this exciting new phase for Christ Church Life Sciences at Discovery Park.” Discovery Park, which is based at the former Pfizer site at Sandwich, is Europe’s leading science and technology park. Providing world class facilities, a host of international companies from the life science, pharmaceutical, biotechnology, science and technology sectors are now based on the site.

Paul Barber, Managing Director for Discovery Park, said:

“The opening of Canterbury Christ Church University’s new facility at Discovery Park is fantastic news – not least for the next generation of scientists who, we hope, will go on to great careers here on site.

“The new laboratory is the first to open in the restored Building 500, helping to continue the story of scientific discovery that this site has been famous for over the decades.”

Read how bio-analysis and logistics firm @A4PBio have used @DiscoveryPark_ as a platform for success… twitter.com/i/web/status/8…
Swing into action at the Discovery Park Classic! Join us at @Princesgolfclub on July 20! #DPTenantCommunity pic.twitter.com/owdVpovp1O
The sale of Agalimmune to @BioLineRx_Ltd is based in no small part on research taking place here in #Sandwich pharmabiz.com/NewsDetails.as… 2/2
 OUR DIGITAL BROCHURE